FDA Answers sNDA For Spectrum's Fusilev With "Complete Response"
This article was originally published in The Pink Sheet Daily
Executive Summary
If two therapies perform similarly in a head-to-head trial, can a sponsor use the failed superiority data to claim non-inferiority? Spectrum hopes so.